Antibiotics + Chemotherapy for Colorectal Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether adding a combination of antibiotics (ciprofloxacin and metronidazole) and aspirin to standard chemotherapy can improve treatment outcomes for people with stage IV colorectal cancer. It includes two groups: one receiving chemotherapy alone, and the other receiving the added antibiotics and aspirin to determine if it enhances cancer treatment. Individuals diagnosed with stage IV colorectal cancer and set to begin their first-line chemotherapy might be suitable candidates for this study. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of participants.
Will I have to stop taking my current medications?
The trial requires you to stop taking disulfiram, tizanidine, or theophylline for the length of the microbiome modulation therapy. If you are on full dose anticoagulation, you may need to lower the dose by half before starting the study drugs. If you are taking methotrexate at doses of 15 mg/week or more, you cannot participate in the trial.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Previous studies have shown that aspirin reduces the risk of colorectal cancer returning by 55%. This suggests it is well-tolerated by many patients and could be safe to use. Metronidazole has also lowered the chance of cancer spreading to the liver after colorectal cancer surgery. When combined with metronidazole and aspirin, ciprofloxacin might help reduce cancer-related bacteria when given with standard chemotherapy.
As this trial enters its second phase, some safety information is available, but further testing will ensure its safety and effectiveness for patients. These results suggest the treatment could be safe, but more information will be gathered during the trial.12345Why are researchers excited about this trial's treatments?
Researchers are excited about the combination of antibiotics and standard chemotherapy for colorectal cancer because it introduces a novel approach by modulating the gut microbiome. This treatment adds metronidazole, ciprofloxacin, and aspirin to the usual chemotherapy regimen, aiming to enhance its effectiveness. Unlike traditional treatments like FOLFOX or FOLFIRI, which primarily target cancer cells directly, this method potentially improves patient response by altering the gut bacteria, which might play a role in cancer progression. This innovative angle of targeting the microbiome is what sets this treatment apart and holds promise for better outcomes.
What evidence suggests that this trial's treatments could be effective for stage IV colorectal cancer?
In this trial, one group of participants will receive a combination of metronidazole, ciprofloxacin, and aspirin alongside standard chemotherapy to explore potential benefits for treating stage IV colorectal cancer. Research has shown that metronidazole can reduce the chance of cancer spreading to the liver after surgery. Ciprofloxacin and metronidazole may also decrease harmful bacteria linked to cancer. Studies have found that low-dose aspirin can lower the risk of colorectal cancer returning in some patients. Specifically, one study showed that people taking aspirin had a slightly better chance of being cancer-free after five years compared to those who did not take it.14567
Who Is on the Research Team?
Emily Kinsey, MD
Principal Investigator
Virginia Commonwealth University
Are You a Good Fit for This Trial?
This trial is for individuals with stage IV colorectal cancer. Participants should be starting their first chemotherapy treatment. The trial excludes those who have had previous treatments for CRC, are allergic to the antibiotics or aspirin being tested, or have other health conditions that could interfere with the study.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive standard of care chemotherapy with or without MBMT, including metronidazole, ciprofloxacin, and aspirin for 28 days
Follow-up
Participants are monitored for safety and effectiveness after treatment, including overall survival and progression-free survival
What Are the Treatments Tested in This Trial?
Interventions
- Aspirin
- Ciprofloxacin
- Metronidazole
- Standard of Care Chemotherapy
Trial Overview
The study is testing if adding antibiotics (ciprofloxacin and metronidazole) and aspirin to standard chemotherapy improves outcomes in stage IV colorectal cancer patients. It's a phase 2 trial with two groups: one receiving just chemo, and the other getting chemo plus these additional medications.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
First line chemo therapy (standard of care) + Microbiome modulation therapy MBMT 500 mg metronidazole 3 times daily, 500 mg ciprofloxacin twice daily, and 81 mg aspirin once daily for 28 days
First line chemotherapy as directed. Standard of care chemotherapy treatment options include but are not limited to the following: * FOLFOX every 2 weeks * FOLFIRI every 2 weeks * FOLFOX + bevacizumab or panitumumab every 2 weeks * FOLFIRI + bevacizumab or panitumumab every 2 weeks * CAPEOX every 3 weeks * CAPEOX + bevacizumab or panitumumab every 3 weeks
Standard of Care Chemotherapy is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:
- Various cancers including breast, lung, colon, pancreatic, and others
- Various cancers including breast, lung, colon, pancreatic, and others
- Various cancers including breast, lung, colon, pancreatic, and others
- Various cancers including breast, lung, colon, pancreatic, and others
- Various cancers including breast, lung, colon, pancreatic, and others
- Various cancers including breast, lung, colon, pancreatic, and others
Find a Clinic Near You
Who Is Running the Clinical Trial?
Virginia Commonwealth University
Lead Sponsor
American Cancer Society, Inc.
Collaborator
Citations
Ciprofloxacin, Metronidazole, and Aspirin with Standard of ...
Ciprofloxacin, metronidazole and aspirin may reduce the amount of cancer-associated bacteria and, when given with first-line standard of care chemotherapy, may ...
The Comparative Effectiveness of Ciprofloxacin and ...
We demonstrated no significant difference in the real-world effectiveness of ciprofloxacin, metronidazole, or combination therapy for the initial episode of ...
Aspirin May Reduce Risk of Colorectal Cancer Recurrence ...
A simple intervention of low-dose aspirin reduces the risk of colorectal cancer recurrence for patients with genetic changes in the PI3K signaling pathway.
Can Aspirin Improve Colorectal Cancer Outcomes?
At five years, disease-free survival rates were 77.0% in the aspirin group versus 74.8% in the placebo group. This reflects a 9% lower risk of ...
5.
trialsjournal.biomedcentral.com
trialsjournal.biomedcentral.com/articles/10.1186/s13063-023-07628-yA prospective, single-centre, randomized, double-blind ... - Trials
... metronidazole can effectively reduce the incidence of postoperative liver metastasis in patients with colorectal cancer. Rui Qi Gao ORCID ...
Morbidity After Mechanical Bowel Preparation and Oral ...
Findings of this randomized clinical trial indicate that MOABP reduced overall postoperative complications as well as rates of SSIs and anastomotic dehiscences.
Aspirin and colorectal cancer: the promise of precision ...
Several decades of research have provided considerable evidence demonstrating its potential for the prevention of cancer, particularly colorectal cancer.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.